Introduction {#Sec1}
============

The single most effective therapy to limit myocardial infarct size and improve clinical outcome after acute myocardial infarction is early coronary reperfusion via primary percutaneous coronary intervention \[[@CR41], [@CR43]\]. However, despite its overall benefits, reperfusion therapy has been shown to result in additional cardiomyocyte death, termed lethal reperfusion injury \[[@CR12], [@CR19], [@CR52]\], and in microvascular obstruction, termed no-reflow \[[@CR38]\]. No-reflow refers to inadequate myocardial reperfusion following opening of the culprit coronary lesion, despite lack of angiographic evidence of epicardial vessel obstruction and may be present in 30--40 % of patients \[[@CR34]\]. Since both infarct size \[[@CR30]\] and extent of no-reflow \[[@CR17], [@CR33], [@CR38]\] are independent predictors of clinical outcome, strategies to limit these two components of reperfusion injury have significant therapeutic potential.

A novel strategy against ischemia--reperfusion injury was proposed by Katare et al. \[[@CR21]\], who demonstrated that vagal nerve stimulation (VNS) limited infarct size in rats. This initial observation was confirmed in subsequent studies in rats \[[@CR8], [@CR25], [@CR48], [@CR54]\], mice \[[@CR22]\] and swine \[[@CR40]\]. In these studies, VNS was started either before \[[@CR8], [@CR21], [@CR54]\], at the very onset of \[[@CR22], [@CR25], [@CR40]\], or halfway through \[[@CR39], [@CR48]\] the period of ischemia. In contrast, a recent study reported that an intermittent VNS protocol failed to attenuate infarct size when started at the very onset of reperfusion \[[@CR39]\]. In view of the critical importance of the presence of an intervention during the golden first minute(s) of reperfusion \[[@CR42]\], we hypothesized that continuous VNS started just prior to reperfusion might be effective against reperfusion injury. Consequently, the first aim of the present study was to investigate the effects of continuous VNS starting 5 min prior to reperfusion \[to ensure full VNS during the first minute(s) of reperfusion\] on infarct size in a large animal model of ST-elevation myocardial infarction (STEMI). Moreover, since none of the aforementioned studies assessed the effects of VNS on no-reflow, despite its prognostic potential in the clinical setting \[[@CR17], [@CR33], [@CR38]\], the second aim of the present study was to investigate the effects of VNS on no-reflow.

The mechanisms underlying the cardioprotective effects of VNS against myocardial necrosis are incompletely understood, but have been proposed to include activation of muscarinic receptors \[[@CR40]\] and blunting of the inflammatory response \[[@CR48]\]. Consequently, the second aim of the present study was to investigate the potential mechanisms underlying the effects of VNS on infarct size and no-reflow, in particular anti-inflammatory actions, including circulating inflammatory cytokines and myocardial neutrophil and macrophage infiltration, and the nitric oxide synthase (NOS) signaling pathway.

Materials and methods {#Sec2}
=====================

Studies were performed in 63 Yorkshire × Landrace swine (\~55 kg) of either sex, in accordance with the "Guiding Principles in the Care and Use of Laboratory Animals" as approved by the Council of the American Physiological Society, and with approval of the Animal Care Committee of the Erasmus MC Rotterdam.

Animal preparation {#Sec3}
------------------

Swine were sedated with ketamine (20 mg/kg, i.m.) and midazolam (1 mg/kg, i.m.), anesthetized with pentobarbital (15 mg/kg i.v.), intubated and mechanically ventilated with O~2~ and N~2~ (1:3 v/v), and instrumented as previously described \[[@CR26], [@CR44]\]. Catheters were placed in the external jugular vein for maintenance of anesthesia (pentobarbital, 10--15 mg/kg/h) and infusion of physiological saline, and the left femoral artery for measurement of arterial blood pressure. A Swan--Ganz catheter was inserted into the left femoral vein and advanced into the pulmonary artery for body core temperature monitoring. A micromanometer-tipped catheter (SPC-3705, Millar Instruments, Houston, USA) was inserted into the right carotid artery and advanced into the left ventricle (LV) for measurement of LV pressure and its first derivative (LVdP/dt). Following sternotomy, an electromagnetic flow probe (P18, Skalar Medical, Delft, The Netherlands) was placed around the ascending aorta to measure cardiac output, and a transit-time flow probe (3SB, Transonic Systems, Ithaca, USA) was placed around the left anterior descending coronary artery (LAD) for measurement of coronary blood flow. A suture was placed around the LAD, just distal to its first diagonal branch, to enable coronary artery occlusion (CAO) during the experimental protocol. Regional myocardial function was measured in the area at risk and remote myocardium using two pairs of ultrasonic crystals (P/N SL5-2, Triton Technology Inc., San Diego, USA) placed in the mid-myocardium \[[@CR11], [@CR44]\]. A fluid-filled catheter was placed in the left atrium through a purse-string suture into the auricle for measurement of left atrial pressure. For coronary venous blood sampling, a custom fluid-filled catheter was placed in the anterior coronary vein draining the perfusion territory of the LAD. Heparin (5000 i.u./h, i.v.) was administered throughout the experiment to prevent coagulation.

Custom-made, self-coiling cuff electrodes were placed around both the left and right vagal nerves for VNS. After completion of instrumentation, the cardiac vagal nerve reserve (maximal percent reduction in heart rate) was tested in both vagal nerves (left and right) in 1 min intervals by increasing voltages (Medtronic 3625 test simulator; 2.0--10.5 V; 10 mA; pulse width 0.3 ms; 25 Hz). The maximum effect of VNS was reached during stimulation with 10.5 V. Maximum heart rate reductions during therapy, produced by stimulation of either left (15 ± 2 %) or right vagal nerve (18 ± 3 %), were not different (*p* = 0.41). Maximum heart rate reductions at pre-ischemia baseline were also comparable between VNS (23 ± 2 %) and sham (21 ± 3 %) groups (*p* = 0.69).

Experimental protocols {#Sec4}
----------------------

### Cardioprotection by VNS {#Sec5}

After 30 min of stabilization, swine were subjected to the experimental protocol. Systemic and coronary hemodynamics and regional myocardial function were continuously recorded. Blood samples were obtained from the aorta and anterior interventricular coronary vein at several time points for measurement of PO~2~ (mmHg), PCO~2~ (mmHg), pH, O~2~ saturation (%), hemoglobin (Hb, in grams per 100 ml) and lactate (μmol/l) (Acid--Base Laboratory model 800, Radiometer, Copenhagen, Denmark). Body core temperature was monitored and maintained between 37.0 and 38.0 °C throughout the experimental protocol \[[@CR13]\]. Swine were subjected to a 45-min CAO followed by 120 min of reperfusion. Swine encountering ventricular fibrillation (VF) were allowed to complete the protocol if conversion to sinus rhythm was successful within 2 min after onset of VF. Swine were randomly assigned to either sham treatment (*n* = 13) or VNS alone (*n* = 17). VNS was started 5 min before the end of CAO and continued until 15 min into reperfusion. All VNS animals were initially subjected to stimulation of the left vagal nerve. In five animals, in which the reduction in heart rate during the first minute was less than 10 %, right vagal nerve stimulation was applied during the remainder of the 20-min stimulation protocol.

### Role of NO-synthase {#Sec6}

To investigate the role of NO signaling in the protection by VNS, we performed a second series of experiments in which we studied three additional groups of swine. Animals underwent the identical 45-min CAO and 120-min reperfusion protocol, as outlined above, while receiving (1) control--sham treatment (*n* = 11), (2) NO-synthase inhibition, using *N*^ω^-nitro-[l]{.smallcaps}-arginine (LNNA, Sigma, Zwijndrecht, The Netherlands) 10 mg/kg i.v. 30 min before CAO \[[@CR27]\], and sham treatment (*n* = 10), or (3) LNNA and VNS (*n* = 12).

Infarct size and area of no-reflow {#Sec7}
----------------------------------

At the end of 120 min of reperfusion, a fluid-filled catheter was inserted into the coronary artery, distal to the site of occlusion, to administer 5 ml of a 4 % (w/v) thioflavin-S (Sigma) solution to determine the area of no-reflow \[[@CR36], [@CR45]\]. The coronary artery was re-occluded and the area at risk was delineated by intra-atrial infusion of 40 ml of 15 % (w/v) Evans Blue \[[@CR13], [@CR26]\]. Then, the heart was excised, the LV was isolated and cut into five transverse slices of equal thickness, and slices were weighed. After the area at risk and area of no-reflow (using UV light) of each slice were demarcated on an acetate sheet, the slices were incubated in 3 % (w/v) 2,3,5-triphenyltetrazolium chloride at 37 °C for 15 min to stain metabolically active tissue \[[@CR13]\] and delineate infarcted area from non-infarcted area. The red stained non-infarcted area was also traced onto the sheet. The area at risk, area of no-reflow, and infarct area from each of the five transverse slices were determined and summed. Myocardial infarct size (IS) was defined as the ratio of the summed infarct areas (IA) and summed areas at risk (AR): IS = IA/AR × 100 % \[[@CR13], [@CR26]\]. Area of no-reflow (NR) was defined as the ratio of the summed no-reflow areas (NA) and summed infarct areas: NR = NA/IA × 100 % \[[@CR36]\].

Systemic inflammation {#Sec8}
---------------------

Plasma isolated from arterial blood taken at baseline, prior to CAO, and the first hour of reperfusion was analyzed by ELISA according to the manufacturer's instructions for porcine inflammatory markers TNFα and IL6 (R&D Systems, Abingdon, UK).

Regional inflammation {#Sec9}
---------------------

Infarct area with either reflow or no-reflow and remote non-area at risk (posterior wall) LV tissue was fixed in 4 % buffered formaldehyde and embedded in paraffin. To identify the acute influx of immune cells, sections of 4 µm were stained for neutrophils (Azurocidin, mouse anti human, 1:100, Abnova, Heidelberg, Germany) following antigen retrieval (10 min citrate buffer boil (pH 6)) and for macrophages (MAC387, mouse anti macrophage, 1:100, Abcam, Cambridge, United Kingdom). Staining was visualized using rabbit anti-mouse secondary antibodies (1:100, horseradish peroxidase label, DAKO, Heverlee, Belgium) with 3,3′-diaminobenzidine (DAB, DAKO) and H~2~O~2~ as chromogen. Primary antibodies were omitted as a negative control. Three randomly selected high power fields (90,000 µm^2^ per field) per section were morphometrically quantified in a blinded manner using dedicated software (Clemex Vision PE, version 6.0.010A, Clemex Technologies inc, Longueuil, Canada). Data were expressed as the number of cells/mm^2^.

Data and statistical analysis {#Sec10}
-----------------------------

Hemodynamic and LV global and regional function data were recorded and analyzed, and myocardial oxygen and lactate consumption, and systolic and post-systolic shortening were calculated, as previously described \[[@CR26], [@CR44]\].

Inter-group differences in AR/LV, IA/AR and NR/IA were analyzed using unpaired *t* test or one-way ANOVA followed by Student--Newman--Keuls (SNK) post hoc testing, as appropriate. Hemodynamics and LV function were analyzed using two-way (time × treatment) ANOVA followed by SNK test. Global and regional inflammation were also analyzed using two-way (treatment × location) ANOVA followed by SNK test. Values are expressed as mean ± SEM. *p* \< 0.05 (two tailed) was considered to be statistically significant.

Results {#Sec11}
=======

Mortality {#Sec12}
---------

In the first series of experiments, 26 out of 30 swine (11 out of 13 sham, 15 out of 17 VNS) encountered VF during the 45 min of CAO (all prior to VNS or sham). Seven out of these 26 swine (3 out of 11 sham, 4 out of 15 VNS) could not be successfully converted to sinus rhythm within 2 min and were therefore excluded from further study. The numbers of animals that encountered VF but could be converted to sinus rhythm within 2 min and completed the experimental protocol were not different (*p* = 0.76) between sham (8 out of 10 swine; 80 %) and VNS (11 out of 13 VNS; 85 %). Moreover, the average number of VF episodes before the start of VNS (1.8 ± 0.4) or sham (1.4 ± 0.4) treatment in these animals was also similar between groups (*p* = 0.45). Importantly, VF did not occur during VNS or the corresponding sham period or after 15 min of reperfusion, except for one sham animal that encountered VF at 11 and 15 min of reperfusion.

In the second series of experiments, 11 out of 11 (100 %) control--sham, and 17 out of 22 (77 %) LNNA-treated swine (*p* = 0.09) encountered VF during the 45 min of CAO (all prior to sham or VNS treatment). However, of the animals that encountered VF, 53 % (9 out of 17) LNNA-treated swine versus 27 % (3 out of 11) control--sham animals (*p* = 0.19) could not be successfully converted to sinus rhythm within 2 min and hence did not complete the experimental protocol. Finally, two swine (LNNA + VNS) developed progressive pump failure during reperfusion and could not complete the experimental protocol.

Hemodynamics and global and regional LV function {#Sec13}
------------------------------------------------

Coronary artery occlusion of the LAD produced complete loss of regional systolic segment shortening, accompanied by an increase in post-systolic shortening in the LAD perfusion territory, which resulted in decreases in LV systolic pressure, LVdP/dt~*P*40~, stroke volume, cardiac output, and mean aortic pressure (Table [1](#Tab1){ref-type="table"}). Global and regional LV function remained severely depressed during the 120-min reperfusion period.Table 1Systemic hemodynamics and global and regional left ventricular functionBaselineCoronary artery occlusionReperfusion40 min45 min15 min120 min*Systemic hemodynamics*HR (bpm) Sham111 ± 6117 ± 8116 ± 8113 ± 7109 ± 5 VNS103 ± 4107 ± 487 ± 4\*^†‡^89 ± 3\*^†‡^109 ± 4MAP (mmHg) Sham94 ± 382 ± 3\*80 ± 3\*76 ± 4\*73 ± 3\* VNS91 ± 377 ± 5\*65 ± 5\*^†^65 ± 4\*^†^71 ± 3\*CO (l/min) Sham4.2 ± 0.33.4 ± 0.1\*3.3 ± 0.1\*3.3 ± 0.2\*2.8 ± 0.1\*^†^ VNS3.5 ± 0.12.9 ± 0.2\*2.3 ± 0.1\*^†‡^2.4 ± 0.2\*^†^2.5 ± 0.1\*^†^SV (ml) Sham38 ± 230 ± 2\*30 ± 2\*30 ± 2\*26 ± 2\* VNS34 ± 227 ± 1\*27 ± 2\*28 ± 2\*23 ± 2\**Global and regional LV function*LVSP (mmHg) Sham109 ± 395 ± 3\*93 ± 3\*90 ± 3\*85 ± 4\* VNS106 ± 290 ± 5\*78 ± 5\*^†^79 ± 4\*^†^85 ± 3\*LVdP/dt~*P* = 40~ (mmHg/s) Sham1700 ± 1601340 ± 80\*1320 ± 60\*1330 ± 80\*1120 ± 60\* VNS1600 ± 701250 ± 80\*1060 ± 70\*1100 ± 80\*1110 ± 50\*LVEDP (mmHg) Sham14 ± 116 ± 115 ± 116 ± 115 ± 1 VNS13 ± 117 ± 1\*16 ± 1\*18 ± 1\*16 ± 1\*SS~LAD~ (%) Sham15.1 ± 1.4−7.2 ± 1.0\*−5.9 ± 0.7\*0.7 ± 0.4\*0.2 ± 0.6\* VNS21.2 ± 1.2−8.8 ± 1.3\*−7.0 ± 1.2\*2.0 ± 1.2\*0.1 ± 1.3\*SS~LCx~ (%) Sham17.2 ± 2.212.8 ± 2.0\*12.8 ± 1.9\*13.9 ± 1.3\*10.8 ± 1.1\* VNS17.2 ± 1.417.4 ± 1.217.7 ± 1.318.1 ± 1.415.4 ± 1.2PSS~LAD~ (%) Sham0.9 ± 0.210.7 ± 1.3\*9.0 ± 1.1\*2.3 ± 0.4^†^2.9 ± 0.7^†^ VNS1.2 ± 0.415.0 ± 1.1\*12.5 ± 1.1\*^†^4.3 ± 1.3\*^†^5.0 ± 1.4\*^†^PSS~LCx~ (%) Sham0.5 ± 0.21.2 ± 0.51.1 ± 0.50.3 ± 0.10.7 ± 0.2 VNS0.8 ± 0.21.1 ± 0.31.2 ± 0.11.0 ± 0.31.3 ± 0.6Data are mean ± SEM; sham group, *n* = 10; VNS group, *n* = 13. Except for CO (*p* = 0.004) and SS~LAD~ (*p* \< 0.001), no differences between groups at baseline*CO* cardiac output, dP/dt~*P* = 40~ rate of rise in left ventricular (LV) pressure during LV pressure of 40 mmHg, *HR* heart rate, *LVEDP* left ventricular end-diastolic pressure, *LVSP* left ventricular systolic pressure, *MAP* mean arterial pressure, *PSS* post-systolic shortening, *SS* systolic shortening, *SV* stroke volume, *VNS* vagal nerve stimulation\* *p* \< 0.05 versus corresponding baseline;^†^ *p* \< 0.05 versus corresponding 40 min CAO;^‡^ *p* \< 0.05 change by VNS versus corresponding sham

The 18 ± 2 % decrease in heart rate produced by VNS was associated with a 19 ± 2 % decrease in cardiac output and a 16 ± 4 and 13 ± 3 % decrease, respectively, in mean aortic and LV peak systolic pressure at 45 min of CAO (Table [1](#Tab1){ref-type="table"}). VNS did not alter LVdP/dt~*P*40~, LV end-diastolic pressure, or regional systolic and post-systolic segment shortening, indicating that VNS did not affect global or regional LV function. These effects of VNS were maintained during reperfusion, although heart rate showed partial escape from VNS during the first 5 min of reperfusion, which was likely due to the occurrence of premature ventricular contractions. After the termination of VNS, systemic hemodynamics and global and regional LV function were no longer different between VNS and sham swine.

Coronary blood flow and myocardial metabolism {#Sec14}
---------------------------------------------

During reperfusion, transient increases in coronary blood flow and coronary vascular conductance were observed, together with a transient reversal from lactate consumption to production and a sustained depression of oxygen consumption (Table [2](#Tab2){ref-type="table"}).Table 2Regional coronary blood flow and myocardial metabolismBaselineReperfusion15 min120 minCBF (ml/min) Sham20 ± 434 ± 6\*22 ± 3 VNS15 ± 126 ± 4\*21 ± 2CBF (ml/beat) Sham0.17 ± 0.030.30 ± 0.05\*0.21 ± 0.03 VNS0.14 ± 0.010.30 ± 0.06\*0.20 ± 0.02MVO~2~ (µmol/min) Sham90 ± 2036 ± 6\*28 ± 4\* VNS67 ± 729 ± 5\*23 ± 3\*MVO~2~ per beat (µmol/beat) Sham0.77 ± 0.130.32 ± 0.05\*0.26 ± 0.03\* VNS0.65 ± 0.130.33 ± 0.05\*0.21 ± 0.03\*CVC (ml/min/mmHg) Sham0.21 ± 0.050.43 ± 0.05\*0.31 ± 0.04 VNS0.16 ± 0.020.32 ± 0.05\*0.29 ± 0.02\*Lactate production (µmol/l/min) Sham−14 ± 510 ± 5\*−7 ± 2 VNS−7 ± 110 ± 2\*−4 ± 2O~2~ Extraction (%) Sham73 ± 219 ± 2\*21 ± 3\* VNS71 ± 219 ± 2\*17 ± 2\*Lactate extraction (%) Sham24 ± 4−13 ± 6\*9 ± 3 VNS24 ± 5−15 ± 3\*6 ± 3\*Data are mean ± SEM; sham group, *n* = 10; VNS group, *n* = 13*CBF* coronary blood flow, *CVC* coronary vascular conductance (CBF/MAP), *MVO* ~*2*~ myocardial oxygen consumption, *O* ~*2*~ *extraction* myocardial oxygen extraction\* *p* \< 0.05 versus corresponding baseline;^†^ *p* \< 0.05 change by VNS versus corresponding sham

There were no significant differences between VNS and sham swine in the responses of coronary blood flow, coronary vascular conductance, myocardial consumption, and extraction of oxygen or lactate during early reperfusion (Table [2](#Tab2){ref-type="table"}; Supplemental Figure S1).

Infarct size and area of no-reflow {#Sec15}
----------------------------------

Ligation of the LAD distal to the first diagonal branch resulted in an average area at risk of 26 ± 1 % of the LV (Figs. [1](#Fig1){ref-type="fig"}, [2](#Fig2){ref-type="fig"}) and did not differ between sham (26 ± 1 %) and VNS (27 ± 1 %; *p* = 0.60). CAO of 45 min resulted in an infarct size in sham swine of 67 ± 2 % of the area at risk and a no-reflow area of 54 ± 6 % of the infarct area. VNS reduced infarct size to 54 ± 5 %, which was accompanied by a decrease in no-reflow area to 32 ± 6 % (both *p* = 0.03). There were no differences between swine undergoing left or right VNS, in terms of infarct size (left 52 ± 7 vs. right 58 ± 7 %, *p* = 0.56) or no-reflow area (left 32 ± 9 vs. right 32 ± 10 %, *p* = 1.00).Fig. 1Typical examples of effects of VNS on infarct size and no-reflow. No-reflow is typically located subendocardiallyFig. 2Effects of VNS on infarct size and no-reflow of sham (*white square*) and VNS (*black square*) animals. Data are mean ± SEM; \**p* \< 0.05 versus sham

Systemic and regional inflammation {#Sec16}
----------------------------------

Systemic TNFα levels did not rise in the early phase after reperfusion, while IL6 increased significantly compared to baseline but no differences between treatment groups were found (Fig. [3](#Fig3){ref-type="fig"}).Fig. 3Effects of VNS on early systemic markers for inflammation. Shown are the effects of treatment on TNFα and IL6 levels in circulating plasma of sham (*white square*) and VNS (*black square*) animals. Data are mean ± SEM; \**p* \< 0.05 versus corresponding baseline

In control animals, neutrophil and macrophage numbers were increased in the infarct area as compared to the remote myocardium, measured after 120 min of reperfusion. VNS attenuated neutrophil as well as macrophage influx into the infarct area (Figs. [4](#Fig4){ref-type="fig"}, [5](#Fig5){ref-type="fig"}).Fig. 4Typical examples of effects of VNS on regional leukocyte presence. Shown are macrophage and neutrophil influx in remote, infarct--reflow and infarct--no-reflow tissue of sham and VNS animalsFig. 5Effects of VNS on regional inflammation. Shown are the effects of treatment on neutrophil and macrophage numbers in remote, total infarct, infarct--reflow and infarct--no-reflow tissue of sham (*white square*) and VNS (*black square*) animals. Data are mean ± SEM; \**p* \< 0.05 versus corresponding remote area; ^†^ *p* \< 0.05 versus corresponding sham; ^‡^ *p* \< 0.10 versus sham

Role of NO-synthase {#Sec17}
-------------------

Infusion of LNNA in 11 swine resulted in an 18 ± 5 % increase in mean arterial pressure from 91 ± 4 to 108 ± 8 mmHg, which was accompanied by a 9 ± 1 % decrease in heart rate from 107 ± 7 to 98 ± 6 bpm, and an 18 ± 2 % decrease in cardiac output from 3.9 ± 0.1 to 3.2 ± 0.1 l/min (all *p* \< 0.01). LNNA did not affect the responses to ischemia and reperfusion of systemic hemodynamics and global and regional LV function (Supplemental Table S1), or coronary hemodynamics and myocardial metabolism (Supplemental Table S2). Importantly, LNNA did not modify the hemodynamic, functional and metabolic responses to VNS (Supplemental Tables S1 and S2).

LNNA had no effect on infarct size, no-reflow area, or leukocyte influx (Table [3](#Tab3){ref-type="table"}). However, LNNA prevented the VNS-induced limitation of infarct size (71 ± 6 % in LNNA + VNS vs. 65 ± 5 % in LNNA + sham) and no-reflow (22 ± 5 % in LNNA + VNS vs. 13 ± 4 % in LNNA + sham), which was paralleled by the prevention of VNS-induced reduction in leukocyte influx (Table [3](#Tab3){ref-type="table"}).Table 3Effects of NO-synthase inhibitionControl + shamLNNA + shamLNNA + VNS*n* = 8*n* = 5*n* = 6Area at risk (% LV)26 ± 225 ± 327 ± 2Infarct size (% AR)50 ± 465 ± 571 ± 6No-reflow (% AR)4 ± 18 ± 216 ± 4No-reflow (% IA)9 ± 213 ± 422 ± 5*Cell influx in infarct area*Neutrophils (\#/mm^2^)12 ± 27 ± 225 ± 6^†^Macrophages (\#/mm^2^)58 ± 1386 ± 3562 ± 17Data are mean ± SEM*AR* area at risk, *IA* infarct area, *LV* left ventricle, *n* number of animals that survived and completed the experimental protocol\* *p* \< 0.05, LNNA + sham versus control + sham;^†^ *p* \< 0.05, LNNA + sham versus LNNA + VNS

Role of changes in hemodynamic determinants of myocardial oxygen demand {#Sec18}
-----------------------------------------------------------------------

Since VNS produced decreases in heart rate and LV systolic pressure, it could be argued that changes in the hemodynamic determinants of myocardial oxygen demand contributed to the cardioprotection by VNS. However, the observation that LNNA abolished the VNS-induced cardioprotection at a time when the hemodynamic effects of VNS were unmitigated suggests that the cardioprotective effects of VNS were independent of its hemodynamic effects. Indeed, regression analysis did not reveal a significant correlation between either infarct size (*r*^2^ = 0.071) or no-reflow area (*r*^2^ = 0.075), and the double product of heart rate and systolic arterial pressure (Fig. [6](#Fig6){ref-type="fig"}).Fig. 6Lack of correlation between the double product of heart rate and systolic arterial pressure and infarct size (*left panel*) and no-reflow (*right panel*) at onset of reperfusion (45 min CAO)

Discussion {#Sec19}
==========

The present study is the first to investigate the effect of VNS started just prior to and continued during early reperfusion on both infarct size and extent of no-reflow in a large animal model of STEMI, using a clinically translational protocol. The main findings were that (1) VNS significantly limited infarct size and extent of no-reflow; (2) these effects were accompanied by reductions in regional infiltration of neutrophils and macrophages; (3) Inhibition of NO-synthase prevented the cardioprotection by VNS against necrosis, no-reflow and leukocyte influx.

Infarct size {#Sec20}
------------

Several studies, though not all \[[@CR3], [@CR4]\], indicate that VNS limits infarct size, when started prior to \[[@CR8], [@CR21], [@CR54]\], at \[[@CR22], [@CR25], [@CR40]\] or halfway through \[[@CR39], [@CR48]\] the onset of myocardial ischemia (Table [4](#Tab4){ref-type="table"}). The majority of these studies have been performed in rodents or rabbits, which are sympathetically dominant, and are therefore likely to have a different sympathico-vagal balance than larger mammalian species such as pigs and humans. Although it could be argued that this may enhance the effects of VNS in smaller animal species with low baseline vagal activity, recent studies observed that VNS produced similar reductions in infarct size in swine \[[@CR39], [@CR40]\], suggesting that its cardioprotective effects do not critically depend on basal vagal activity.Table 4Studies on the cardioprotective effects of vagal nerve stimulationReferencesSpeciesI/R timeStart VNSDuration VNSInfarct size (% AR)No-reflow (% IA)*Pre/onset* *ischemia*Katare et al. \[[@CR21]\]Rat30 min/2 h5 min pre-ischemia35 minSham85 ± 3--VNS34 ± 2\*Calvillo et al. \[[@CR8]\]Rat30 min/24 h5 min pre-ischemia40 minSham53 ± 5--VNS7 ± 1\*Zhao et al. \[[@CR54]\]Rat60 min/2 h15 min pre-ischemia75 minSham47 ± 4--VNS27 ± 3\*Kong et al. \[[@CR25]\]Rat4 h/0 hOnset ischemia240 minSham52 ± 2--VNS28 ± 2\*Katare et al. \[[@CR22]\]Mouse3 h/0 hOnset ischemia180 minSham56 ± 1--VNS24 ± 2\*Buchholz et al. \[[@CR3]\]Rabbit30 min/3 h10--15 min pre-ischemia10 minSham52 ± 4--VNS71 ± 4\*Buchholz et al. \[[@CR4]\]Rabbit45 min/4 h10 min pre-ischemia10 minSham45 ± 2--VNS63 ± 3\*I-VNS30 ± 3\*Shinlapawittayatorn et al. \[[@CR40]\]Swine60 min/2 hOnset ischemia180 minSham46 ± 5--VNS19 ± 4\*I-VNS5 ± 2\**Early/mid*-*ischemia*Shinlapawittayatorn et al. \[[@CR39]\]Swine60 min/2 h30 min into ischemia150 minSham46 ± 3--I-VNS19 ± 3\*Wang et al. \[[@CR48]\]Rat30 min/2 h15 min into ischemia30 minSham72 ± 2--VNS47 ± 3\**Pre/onset* *reperfusion*Shinlapawittayatorn et al. \[[@CR39]\]Swine60 min/2 hOnset reperfusion120 minSham46 ± 3--I-VNS44 ± 3Uitterdijk et al.Swine45 min/2 h5 min pre-reperfusion20 minSham67 ± 254 ± 6VNS54 ± 5\*32 ± 6\*Data are mean ± SEM*AR* area at risk, *IA* infarct area, *I/R* infarct/reperfusion time, *IS* infarct size, *VNS* vagal nerve stimulation, *I-VNS* intermittent vagal nerve stimulation (Buchholz: 10 s on/50 s off; Shinlapawittayatorn: 21 s on/30 s off)\* *P* \< 0.05 versus corresponding sham. All studies were conducted in vivo except \[[@CR13]\]

From the studies in Table [4](#Tab4){ref-type="table"}, it is difficult to determine whether the protective effect of VNS occurred during ischemia or whether a reduction in lethal reperfusion injury contributed as well. Two studies in which no reperfusion was allowed \[[@CR22], [@CR25]\] suggest that at least part of the protective effect is targeted against ischemic cell death. Furthermore, a recent study reported that an intermittent VNS protocol failed to attenuate infarct size when started at the very onset of reperfusion \[[@CR39]\], questioning whether VNS can protect against reperfusion injury. In view of the critical importance of the presence of an intervention during the golden first minute(s) of reperfusion \[[@CR42]\], we hypothesized that continuous VNS started just prior to reperfusion might be effective against reperfusion injury. Indeed, we found that VNS, started a few minutes prior to reperfusion, was able to reduce myocardial infarct size, showing its cardioprotective potential against lethal reperfusion injury. The discordance between our findings and the study of Shinlapawittayatorn et al. \[[@CR39]\] may well be due to the difference in VNS algorithm, i.e., intermittent VNS starting at the very onset of reperfusion \[[@CR39]\] versus continuous VNS starting 5 min prior to reperfusion (Table [4](#Tab4){ref-type="table"}), and may thus reflect the importance of full VNS during the golden first minute(s) of reperfusion \[[@CR42]\].

The mechanism by which VNS limits infarct size is presently incompletely understood, but could involve indirect hemodynamic effects. Thus, the decrease in heart rate and the rate--pressure product could lower metabolic demand and modify reactive hyperemia during early reperfusion, thereby generating favorable (gentle) reperfusion conditions \[[@CR32]\]. However, most evidence suggests that VNS-induced cardioprotection is independent of the reduction in heart rate. Thus, Calvillo et al. \[[@CR8]\] showed that restoring the heart rate to baseline levels by atrial pacing did not affect cardioprotection by VNS, while several studies have shown a lack of correlation between the reduction in heart rate and the reduction in infarct size by VNS \[[@CR8], [@CR21], [@CR40]\]. Those findings are supported by the lack of a significant correlation between the rate--pressure product and infarct size in the present study (Fig. [6](#Fig6){ref-type="fig"}). Moreover, coronary reactive hyperemia was not attenuated during VNS (Supplemental Figure S1), which may have been due to the opposing effects of the bradycardia-associated blunted metabolic stimulus for reactive hyperemia and the bradycardia-associated increase in diastolic perfusion time. Taken together, these findings suggest that the VNS-mediated cholinergic activation \[[@CR8]\] and muscarinic receptor stimulation \[[@CR40]\] protect against necrosis principally via a direct myocardial mechanism. Consequently, we studied the involvement of the reperfusion injury signaling kinase pathway, distal to the muscarinic receptor, by investigating the role of NO-synthase \[[@CR9]\]. NO-synthase inhibition abolished VNS-mediated cardioprotection, at a time when the hemodynamic effects of VNS were unperturbed, indicating that cardiac NO-synthase activity was critical for VNS-mediated infarct-size and no-reflow reductions. These observations are in line with studies from our laboratory \[[@CR28], [@CR29]\] showing an important role for nitric oxide in cardioprotection against reperfusion injury, likely by limiting opening of the mitochondrial permeability transition pore \[[@CR36], [@CR39], [@CR40]\]. Future studies are needed to further investigate the molecular underpinnings of VNS-mediated cardioprotection.

No-reflow {#Sec21}
---------

Reperfusion following a prolonged period of myocardial ischemia is associated with microvascular obstruction, termed no-reflow \[[@CR38]\]. No-reflow is the result of endothelial cell damage, deterioration of the glycocalyx, increased neutrophil plugging, micro-embolization, microvessel rupture and edema \[[@CR15], [@CR38]\]. No-reflow has been shown to be a strong clinical prognosticator for long-term outcome \[[@CR33], [@CR38]\], which is, at least in part, due to its close correlation with infarct size \[[@CR18], [@CR31], [@CR45]\]. However, recent studies suggest that not only infarct size \[[@CR30], [@CR51]\], but also the extent of no-reflow \[[@CR17], [@CR33], [@CR38]\] is an independent predictor of clinical outcome, which is supported by experimental studies reporting reductions in no-reflow by hypothermia \[[@CR17]\] or pharmacological intervention \[[@CR27]\], independent of a decrease in myocardial infarct size. These recent insights clearly suggest that novel strategies to limit no-reflow have significant therapeutic potential.

The present study is to our knowledge the first to investigate the effects of VNS on the extent of no-reflow. VNS markedly reduced no-reflow, which was accompanied by a reduction in recruitment of macrophages and neutrophils to the infarct area. These findings suggest that VNS modulates the regional immune response and are consistent with the activation of the cholinergic anti-inflammatory pathway by VNS \[[@CR8], [@CR20], [@CR48]\]. VNS-induced reduction of no-reflow in the infarct area was prevented by NO-synthase inhibition in parallel with the abolition of infarct-size limitation, indicating that NO signaling is critical for the cardioprotective effects of VNS against both cardiomyocyte necrosis and microvascular obstruction.

Methodological considerations {#Sec22}
-----------------------------

An intriguing observation in the present study was that the values for no-reflow of sham animals were considerably higher in the first (Fig. [2](#Fig2){ref-type="fig"}) than in the second (Table [3](#Tab3){ref-type="table"}) series of experiments. The second series of experiments was performed approximately 1--2 years after completing the first series. Plotting all sham--control animals that underwent 45 min of ischemia and 120 min of reperfusion in the first series (2011 + 2012) and in the second series (2013 + 2014) demonstrates that the no-reflow area (and to a lesser extent infarct size) was significantly smaller in the latter period (Supplemental Figure S2). Although an explanation is not readily found (same supplier, same swine breed, same laboratory, same investigators), it should be noted that the first series was principally performed in the period of February--July, whereas the second series was performed in the period of August--January, suggesting that seasonal influences could be involved \[[@CR24]\]. Although the present study does not allow identification of the exact mechanisms underlying these differences, the observations do emphasize the importance of time-matched sham--control experiments, as performed in the present study.

We also observed that while the occurrence of VF was high in both control + sham and LNNA-treated swine, there was a trend toward an increase in intractable VF from 27 % (3 out of 11) in sham animals to 53 % (9 out of 17) in LNNA-treated animals (*p* = 0.19). These findings are not readily explained, but there is evidence that loss of NO bioavailability increases the susceptibility to VF during ischemia--reperfusion \[[@CR2], [@CR6], [@CR23]\]. Importantly, intractable VF invariably occurred prior to randomization to sham or VNS treatment in both control + sham and LNNA-treated animals and hence did not affect the study results.

A potential limitation of the present study is that we studied only the very early effects of VNS on infarct size and no-reflow in swine with acute myocardial infarction, with a follow-up limited to 2-h post-reperfusion. This time point was chosen in view of the demonstrated lack of development of infarct size and no-reflow over time between 2 and 5 h of reperfusion \[[@CR16]\], so that we do not expect that infarct size and no-reflow would have evolved much further beyond the 2-h point. However, the 2-h reperfusion time was clearly insufficient to allow the VNS-mediated infarct-size reduction to translate into significant improvements in regional and global LV function. Future studies are required to investigate the long-term effects of infarct-size and no-reflow reductions by VNS on LV remodeling and function.

Another methodological consideration is the use of pentobarbital anesthesia. Pentobarbital is known to possess vagolytic properties, although this effect appears negligible in swine, as heart rates under pentobarbital anesthesia (\[[@CR7]\]; present study) are not different from the heart rates we typically observe in awake resting swine \[[@CR14]\]. Importantly, even if vagal tone is reduced, the ability to stimulate the vagal nerve and induce bradycardia remains principally intact \[[@CR5]\], suggesting that pentobarbital's vagolytic effects are centrally mediated and do not interfere with efferent vagal nerve stimulation.

In the present study, a custom-made coil to perform VNS was used, which may have contributed to a higher mA than what has been typically used (1--4 mA) in clinical studies \[[@CR10], [@CR35], [@CR53]\] and in a previous study (1--4 mA; 30 Hz, pulse width 0.2 ms) from our laboratory in swine \[[@CR7]\]. The latter was associated with reductions in heart rate of up to \~30 %. Those settings, which are similar to the settings used in VNS for the treatment of epilepsy and are well tolerated \[[@CR37], [@CR46]\], were similar in frequency and pulse duration as used in the present study (25 Hz, 0.3 ms), but the intensity used in the present study (10 mA) was significantly higher. The fact that we produced slightly smaller reductions in heart rate at higher VNS intensities may reflect the custom coil versus the clinical grade coil that we previously had access to. It is important to note that this was a proof-of-concept study that did not test a clinically approved device, but investigated the efficacy of VNS started just prior to reperfusion and continued for only 15 min into reperfusion, in which we were able to demonstrate cardioprotection, despite a modest 20 % reduction in heart rate.

Another limitation of the present study is that only a single VNS protocol was studied and hence it is likely that other VNS algorithms may afford greater cardioprotection \[[@CR25]\]. Optimization of the VNS protocol may include changes in stimulation frequency \[[@CR1]\] and extending the duration of stimulation beyond 15 min of reperfusion.

Clinical implications {#Sec23}
---------------------

The present study demonstrates that VNS starting just prior to and lasting only 15 min into reperfusion is effective in reducing infarct size and no-reflow in a large animal model of reperfused STEMI. VNS thus appears to be an attractive potential adjuvant therapy to limit reperfusion injury in patients with STEMI. The current technology includes implantable stimulators \[[@CR47]\]; but with the ongoing development of transvenous and transdermal \[[@CR49], [@CR50]\] approaches that do not require dissection of the vagal nerve, investigation of VNS in the clinical setting of STEMI appears warranted.

Conclusions {#Sec24}
===========

The present study in a porcine model of acute myocardial infarction demonstrated that vagal nerve stimulation (VNS) started just prior to reperfusion and continued during early reperfusion-limited infarct size and the extent of no-reflow. The cardioprotection appeared to occur independently of the VNS-induced decrease in heart rate and was not associated with a reduction in systemic markers of inflammation. However, VNS did result in reduced neutrophil and macrophage influx into the infarct area. Finally, NO-synthase activity was required for the VNS-induced limitation in infarct size and no-reflow. Taken together, our findings indicate that VNS is a promising novel adjunctive therapy to limit reperfusion injury.

Electronic supplementary material
=================================

 {#Sec25}

###### 

Supplementary material 1 (TIFF 319 kb)

###### 

Supplementary material 2 (TIFF 1622 kb)

###### 

Supplementary material 3 (DOCX 30 kb)

###### 

Supplementary material 4 (DOCX 20 kb)

A. Uitterdijk and T. Yetgin have contributed equally to this work.

Conflict of interest {#d30e2863}
====================

This study was supported in part by Medtronic. Trent M Fischer and Richard N Cornelussen are Medtronic employees.
